Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know
Catalyst Pharmaceutical (CPRX) closed at $11.83 in the latest trading session, marking a +1.37% move from the prior day. The stock outpaced the S&P 500's daily gain of 0.08%. Meanwhile, the Dow lost 0.68%, and the Nasdaq, a tech-heavy index, lost 0.61%.
Coming into today, shares of the specialty drug company had lost 6.71% in the past month. In that same time, the Medical sector lost 0.75%, while the S&P 500 gained 6.1%.
Investors will be hoping for strength from Catalyst Pharmaceutical as it approaches its next earnings release. In that report, analysts expect Catalyst Pharmaceutical to post earnings of $0.26 per share. This would mark year-over-year growth of 30%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $94 million, up 76.98% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $1.13 per share and revenue of $380.69 million. These totals would mark changes of +50.67% and +77.72%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Catalyst Pharmaceutical. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 7.65% lower within the past month. Catalyst Pharmaceutical is currently a Zacks Rank #5 (Strong Sell).
Investors should also note Catalyst Pharmaceutical's current valuation metrics, including its Forward P/E ratio of 10.36. Its industry sports an average Forward P/E of 17.05, so we one might conclude that Catalyst Pharmaceutical is trading at a discount comparatively.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 106, putting it in the top 43% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Catalyst Pharmaceuticals, Inc. (CPRX) : Free Stock Analysis Report
